Immunoco-culture killing model from InnoModels Biotechnology
- Categories:Company news
- Author:InnoModels
- Origin:InnoModels
- Time of issue:2024-09-14 14:54
- Views:
(Summary description)With the continuous development of oncology and immunology, finding more effective treatments has become a common goal for scientists and doctors. In this context, the PBMC-tumor cell co-culture killing platform, an immunoculture killing model launched by InnoModels Biotechnology (Beijing) Co., Ltd. has become an important breakthrough in immunocidal research in vitro. This innovative model not only provides researchers with an experimental platform that is closer to the physiological situation in vivo, but also brings new possibilities for the development and evaluation of immunotherapeutic drugs.
Immunoco-culture killing model from InnoModels Biotechnology
(Summary description)With the continuous development of oncology and immunology, finding more effective treatments has become a common goal for scientists and doctors. In this context, the PBMC-tumor cell co-culture killing platform, an immunoculture killing model launched by InnoModels Biotechnology (Beijing) Co., Ltd. has become an important breakthrough in immunocidal research in vitro. This innovative model not only provides researchers with an experimental platform that is closer to the physiological situation in vivo, but also brings new possibilities for the development and evaluation of immunotherapeutic drugs.
- Categories:Company news
- Author:InnoModels
- Origin:InnoModels
- Time of issue:2024-09-14 14:54
- Views:
INTRODUCTION
With the continuous development of oncology and immunology, finding more effective treatments has become a common goal for scientists and doctors. In this context, the PBMC-tumor cell co-culture killing platform, an immunoculture killing model launched by InnoModels Biotechnology (Beijing) Co., Ltd. has become an important breakthrough in immunocidal research in vitro. This innovative model not only provides researchers with an experimental platform that is closer to the physiological situation in vivo, but also brings new possibilities for the development and evaluation of immunotherapeutic drugs.
Model Introduction:
Core Technology
The PBMC-tumor cell co-culture killing platform of InnoModels Biotechnology employs a mixed culture of peripheral blood mononuclear cells (PBMCs) and tumor cells. By using CFSE-labeled tumor cells and CD45-labeled immune cells, the model is able to accurately distinguish between effector cells (immune cells) and target cells (tumor cells), and validate target cell killing by flow cytometry. This method effectively minimizes the influence of immune cell proliferation and apoptosis on the test results, thus enabling an accurate assessment of killing.
Experimental Procedure
In the experiments, PBMCs and tumor cells were mixed and cultured in appropriate media to mimic the immune-mediated killing response in vivo. By using specific markers for CSFE and CD45, researchers were able to clearly distinguish and quantify tumor cells after killing, as well as the immune cells involved in the killing. Subsequent application of flow cytometry provides detailed information on the interaction of immune cells and tumor cells, including quantitative analysis of the killing effect.
Advantageous features
1. Accuracy: Through precise cell labeling and flow cytometry analysis, the model is able to accurately measure the number of killed cells, ensuring the accuracy of the results.
2. Efficiency: The mitigation of non-specific activation enables the platform to distinguish between specific and non-specific immune responses, providing a comprehensive view of immune cell activity.
3. Physiological relevance: By simulating the immune-mediated killing response in vivo, the platform provides a more physiologically relevant model for research, which is important for the development and evaluation of immunotherapy.
Application Areas:
Immunotherapy development
Evaluating the potential of immune cells to kill tumor cells is key to effective immunotherapy development. InnoModels' PBMC-tumor cell co-culture killing platform can provide researchers with detailed data to support their understanding of the mechanisms and effects of immunotherapy, and thus optimize treatment protocols.
Drug Screening
The model can also be used to assess the effect of potential drugs or compounds on immune-mediated killing, helping scientists screen drugs with development potential. This capability is particularly important during the new drug discovery phase and can significantly accelerate the drug discovery process.
Immunology Research
An in-depth understanding of the mechanism of immune cell killing and its relationship with non-specific activation is an important part of immunological research. The platform provides powerful research tools that enable researchers to explore these complex interactions in depth.
Personalized Medicine
Tailoring therapeutic regimens based on an individual patient's immune response is an important tool for improving treatment outcomes. The models of InnoModels Biotechnology can be applied to the study of personalized medicine, helping doctors to develop more precise treatment plans.
Future Prospects:
InnoModels Biotechnology not only focuses on the research and development of immune co-culture killing models, but also introduces a variety of immune cell types and constructs more realistic three-dimensional tissue structures to further enhance the biological significance and clinical application value of the models. In the future, with the continuous advancement of technology and in-depth research, this model is expected to play an even more important role in the field of cancer treatment, bringing hope and the chance of recovery to more patients.
In conclusion, InnoModels' immune co-culture killing model is an important tool to promote immunotherapy research, which not only provides researchers with a precise and efficient research platform, but also offers new possibilities for the future development of cancer therapy. We believe that with the joint efforts of scientists and doctors, this model will show a broader development prospect in the field of oncology.
- Tel 15010000264
- E-mail limy@imodels.tech
- Tel 13810723384
- Top
InnoModels Biotechnology (Beijing) Co., Ltd.
TEL:15010000264 13810723384
Email:cndw@imodels.tec
Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing
Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company